Payment overview · 2025
General Payments
$341.97
19 reported records · 6 companies
Healthcare provider profile · identity verified
Joseph Lynn Walker, MD
Allopathic & Osteopathic Physicians|Surgery · DONALSONVILLE, GA · NPI 1396866943
Verified facts
What the public records show
CMS Open Payments records show Joseph Lynn Walker, MD received $341.97 in general payments during 2025 across 19 reported records.
Organogenesis Inc. accounted for 65.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $224.61 | 65.7% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.33 | 11.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.90 | 7.0% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $22.42 | 6.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.11 | 5.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.60 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $341.97 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VIA MATRIX Normalized: via matrix |
Medical Supply | Organogenesis Inc. | $75.38 | 4 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $58.11 | 3 | 2025 |
Source payment records
|
|||||
| AFFINITY Normalized: affinity |
Medical Supply | Organogenesis Inc. | $45.94 | 3 | 2025 |
Source payment records
|
|||||
| CYGNUS DUAL Normalized: cygnus dual |
Medical Supply | Organogenesis Inc. | $26.44 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $23.90 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.97 | 1 | 2025 |
Source payment records
|
|||||
| NOVACHOR Normalized: novachor |
Medical Supply | Organogenesis Inc. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 78 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
78 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 460 | 78 |
| Losartan Potassium | Losartan Potassium | 385 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 372 | 74 |
| Simvastatin | Simvastatin | 345 | 74 |
| Potassium Chloride | Potassium Chloride | 295 | 62 |
| Gabapentin | Gabapentin | 294 | 46 |
| Atorvastatin Calcium | Atorvastatin Calcium | 288 | 52 |
| Metformin Hcl | Metformin Hcl | 276 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 267 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 263 | 54 |
| Furosemide | Furosemide | 262 | 56 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 241 | 94 |
| Celecoxib | Celecoxib | 235 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 229 | 41 |
| Montelukast Sodium | Montelukast Sodium | 227 | 65 |
| Tramadol Hcl | Tramadol Hcl | 209 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 169 | 35 |
| Lisinopril | Lisinopril | 167 | 41 |
| Clonazepam | Clonazepam | 159 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 154 | 26 |
| Alprazolam | Alprazolam | 153 | 33 |
| Meloxicam | Meloxicam | 152 | 32 |
| Levofloxacin | Levofloxacin | 133 | 89 |
| Trazodone Hcl | Trazodone Hcl | 133 | 29 |
| Glimepiride | Glimepiride | 129 | 26 |
| Methylprednisolone | Methylprednisolone | 128 | 82 |
| Omeprazole | Omeprazole | 117 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 115 | 42 |
| Eliquis | Apixaban | 114 | 17 |
| Famotidine | Famotidine | 102 | 24 |
| Azithromycin | Azithromycin | 96 | 69 |
| Allopurinol | Allopurinol | 94 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 92 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 81 | 42 |
| Jardiance | Empagliflozin | 80 | 12 |
| Farxiga | Dapagliflozin Propanediol | 78 | 12 |
| Donepezil Hcl | Donepezil Hcl | 76 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 76 | 20 |
| Ozempic | Semaglutide | 74 | 17 |
| Primidone | Primidone | 74 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 71 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 71 | suppressed |
| Prednisone | Prednisone | 71 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 14 |
| Carvedilol | Carvedilol | 66 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 12 |
| Ondansetron Odt | Ondansetron | 58 | 42 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 58 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 55 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 13 |
| Megestrol Acetate | Megestrol Acetate | 55 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 53 | suppressed |
| Sucralfate | Sucralfate | 52 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 43 |
| Divalproex Sodium | Divalproex Sodium | 51 | suppressed |
| Mounjaro | Tirzepatide | 51 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 50 | 12 |
| Cefdinir | Cefdinir | 49 | 40 |
| Ezetimibe | Ezetimibe | 49 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 48 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | 11 |
| Lorazepam | Lorazepam | 45 | 15 |
| Clindamycin Hcl | Clindamycin Hcl | 44 | 35 |
| Meclizine Hcl | Meclizine Hcl | 44 | 23 |
| Sertraline Hcl | Sertraline Hcl | 43 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 31 |
| Linzess | Linaclotide | 41 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 38 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 11 |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 37 | 21 |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | suppressed |
| Chlorthalidone | Chlorthalidone | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 16 |
| Pregabalin | Pregabalin | 35 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 35 | suppressed |
| Bumetanide | Bumetanide | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 32 | 22 |
| Eszopiclone | Eszopiclone | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 20 |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 25 | suppressed |
| Sulindac | Sulindac | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 23 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 23 | 17 |
| Risperidone | Risperidone | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 22 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 17 |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 17 |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 12 |
| Dutasteride | Dutasteride | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Livalo | Pitavastatin Calcium | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $341.97 · 19 records | Organogenesis Inc. | AFFINITY, AIRSUPRA, Auvelity, CYGNUS DUAL, FARXIGA, NOVACHOR, Ozempic, PURAPLY WOUND MATRIX, QUTENZA, Rybelsus, TRELEGY ELLIPTA, VIA MATRIX | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error